background
rna
interfer
conserv
mechan
sequencespecif
genesilenc
process
mediat
small
interf
rna
sirna
promis
method
gene
therapi
treat
varieti
viral
diseas
aim
investig
antivir
effect
sirna
herp
simplex
viru
type
replic
vero
cell
method
antivir
effect
sirna
duplex
target
dna
polymeras
gene
evalu
yieldreduct
plaquereduct
assay
effect
sirna
express
target
gene
measur
realtim
quantit
revers
transcript
pcr
result
two
sirna
duplex
target
target
dna
polymeras
found
highli
effect
inhibit
replic
reduc
replic
around
log
log
yieldreduct
assay
plaquereduct
assay
respect
signific
decreas
mrna
level
dna
polymeras
gene
detect
viral
infect
vero
cell
pretreat
respect
conclus
result
indic
sirna
potent
inhibit
replic
vitro
suggest
sirnabas
antivir
therapi
may
potenti
effect
therapeut
altern
patient
infect
herp
simplex
viru
hsv
linear
doublestrand
dna
viru
primarili
affect
mucocutan
surfac
caus
condit
gingivostomat
pharyng
herp
labiali
genit
herp
occasion
infect
central
nervou
system
viscer
organ
caus
varieti
diseas
rang
sever
mild
sever
may
even
lifethreaten
immunocompromis
patient
major
clinic
signific
hsv
type
lie
abil
caus
acut
primari
infect
reactiv
period
latenc
caus
recurr
infect
aciclovir
nucleosid
deriv
penciclovir
famciclovir
valaciclovir
ganciclovir
approv
worldwid
treatment
herpet
infect
howev
problem
associ
toxic
drug
resist
report
current
specif
drug
avail
elimin
establish
lifelong
infect
rna
interfer
rnai
may
new
approach
hsv
therapi
rnai
genesilenc
mechan
base
sequencespecif
target
posttranscript
mrna
degrad
induc
doublestrand
rna
small
interf
rna
sirna
doublestrand
rna
nucleotid
length
gener
ribonucleas
iii
enzym
dicer
act
function
intermedi
rnai
induc
target
mrna
cleavag
rnainduc
silenc
complex
power
technolog
wide
use
manipul
gene
express
identifi
gene
function
wholegenom
scale
develop
antivir
strategi
prevent
treatment
human
viral
diseas
mani
report
show
sirna
specif
potent
inhibit
number
virus
includ
human
immunodefici
viru
hepat
b
c
virus
sever
acut
respiratori
syndrom
sar
associ
coronaviru
influenza
viru
studi
examin
effect
sirna
replic
vero
cell
found
target
target
dna
polymeras
significantli
inhibit
replic
sirna
duplex
correspond
dna
polymeras
gene
genbank
access
number
respect
design
synthes
genepharma
shanghai
china
sequenc
correspond
sirna
duplex
shown
tabl
vero
cell
african
green
monkey
kidney
cell
line
sun
yatsen
univers
guangzhou
china
cultur
rmpi
medium
gibco
ny
usa
supplement
fetal
calf
serum
co
strain
f
jinan
univers
guangzhou
china
propag
vero
cell
infecti
titr
vero
cell
measur
use
plaqu
assay
transfect
sirna
duplex
vero
cell
seed
plate
concentr
cell
well
grown
overnight
growth
vero
cell
reach
confluenc
pmol
l
sirna
duplex
mix
lipofectin
top
genom
guangzhou
china
ad
cultur
medium
h
transfect
cell
wash
overlaid
fresh
rmpi
medium
fetal
calf
serum
prophylact
therapeut
effect
sirna
investig
accord
previous
describ
method
briefli
prophylact
studi
vero
cell
infect
plaqueform
unit
pfu
cell
h
sirna
transfect
therapeut
studi
vero
cell
infect
h
prior
sirna
transfect
inhibitori
effect
sirna
replic
evalu
previous
describ
yieldreduct
assay
cell
viru
control
well
demonstr
complet
cytopath
effect
cpe
virusinfect
cell
cultur
harvest
subject
three
freez
thaw
cycl
spin
g
min
supernat
collect
store
viru
titrat
perform
limitingdilut
method
use
plate
replic
per
dilut
viru
titr
express
tissu
cultur
infecti
dose
tcid
ml
plaquereduct
assay
inocula
yield
plaqu
per
well
remov
absorpt
period
infect
cell
incub
rmpi
contain
methylcellulos
cp
sigma
st
loui
mo
usa
day
cell
wash
twice
phosphatebuff
salin
stain
crystal
violet
methanol
min
follow
sever
wash
water
number
viral
plaqu
count
intracellular
mrna
level
dna
polymeras
quantifi
realtim
quantit
revers
transcript
rt
pcr
commerci
kit
use
extract
total
rna
rneasi
mini
kit
qiagen
hilden
germani
remov
trace
dna
rnasefre
dnase
kit
qiagen
synthes
cdna
rt
reagent
prophylact
therapeut
effect
replic
investig
compar
control
sirna
sirnac
yield
group
treat
decreas
log
log
respect
fig
viral
plaqu
number
decreas
respect
plaquereduct
assay
fig
fig
reduc
yield
around
log
log
yieldreduct
assay
compar
control
respect
fig
two
activ
sirna
duplex
use
combin
viralinhibit
studi
total
dosag
singl
sirna
duplex
use
control
shown
fig
two
dose
combin
sirna
significantli
inhibit
replic
combin
sirna
duplex
demonstr
improv
potenc
antivir
effect
compar
p
prophylact
therapeut
studi
fig
b
mrna
level
dna
polymeras
measur
realtim
rtpcr
h
h
infect
sirnapretr
cell
result
decreas
mrna
h
postinfect
decreas
h
infect
fig
dna
polymeras
mrna
level
reduc
cell
h
h
postinfect
respect
fig
studi
evalu
inhibitori
effect
synthes
sirna
duplex
correspond
dna
polymeras
gene
replic
encod
gene
virion
phosphoprotein
synthes
late
phase
gene
express
lytic
infect
activ
transcript
immediateearli
gene
result
cascad
gene
transcript
earli
gene
late
gene
transcrib
order
tempor
pattern
abil
transactiv
express
viral
immediateearli
gene
consid
essenti
effici
viral
replic
dna
polymeras
anoth
key
enzym
replic
herpesvirus
drug
avail
treat
herpesviru
infect
target
viral
dna
polymeras
experi
show
sirna
duplex
target
dna
polymeras
gene
potent
inhibit
replic
therefor
dna
polymeras
may
effect
target
gene
inhibit
replic
rnai
previou
studi
shown
combin
multipl
sirna
target
differ
gene
repres
potent
way
enhanc
antivir
activ
compar
target
singl
gene
enhanc
antivir
effect
observ
cotransfect
sirna
target
viral
gene
spike
protein
sar
coronaviru
infect
effect
could
explain
specif
bind
certain
sirna
may
chang
secondari
structur
rna
therefor
result
access
site
sirna
molecul
howev
univers
find
addit
synergist
effect
antivir
activ
observ
studi
use
combin
specif
sirna
target
viral
proteas
sirna
target
untransl
region
start
codon
rna
polymeras
coxsacki
viru
present
studi
synergist
effect
note
two
sirna
duplex
use
reason
discrep
studi
clear
howev
use
multipl
sirna
concurr
remain
attract
approach
develop
clinic
antivir
agent
potenti
limit
viral
escap
due
mutat
data
show
sirna
achiev
potent
inhibit
replic
viral
infect
observ
effect
prophylact
inhibitori
activ
sirna
suggest
potenti
valu
sirna
prevent
measur
infect
recurr
infect
caus
viru
reactiv
moreov
sirna
could
develop
antivir
agent
treatment
infect
strong
therapeut
effect
observ
vitro
although
sirna
appear
promis
antivir
modal
technolog
sever
limit
clinic
applic
deliveri
probabl
biggest
obstacl
develop
sirnabas
therapeut
agent
direct
administr
would
requir
sirna
modifi
resist
nucleas
perhap
conjug
ligand
target
sirna
specif
tissu
addit
problem
identif
effect
target
site
target
gene
activ
interferon
trigger
sirna
probabl
emerg
escap
mutant
need
attent
summari
demonstr
chemic
synthes
sirna
duplex
target
target
dna
polymeras
exhibit
excel
antivir
activ
inhibit
replic
vero
cell
provid
foundat
studi
use
sirna
effect
antivir
agent
infect
